ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

ADXS Ayala Pharmaceuticals Inc (QX)

0.5305
-0.1126 (-17.51%)
02 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Ayala Pharmaceuticals Inc (QX) USOTC:ADXS OTCMarkets Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.1126 -17.51% 0.5305 0.5305 0.665 0.61 0.519 0.55112 5,485 20:24:00

Current Report Filing (8-k)

07/06/2018 2:12pm

Edgar (US Regulatory)


 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

 

FORM 8-K

 

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of report (Date of earliest event reported): June 7, 2018

 

ADVAXIS, INC.

(Exact Name of Registrant as Specified in Charter)

 

Delaware   001-36138   02-0563870

(State or Other Jurisdiction

of Incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

 

305 College Road East

Princeton, New Jersey, 08540

(Address of Principal Executive Offices)

 

(609) 452-9813

(Registrant’s telephone number, including area code)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

  [  ] Written communications pursuant to Rule 425 under the Securities Act.
     
  [  ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act.
     
  [  ] Pre-commencement communications pursuant to Rule 14d-2b under the Exchange Act.
     
  [  ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company [  ]

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [  ]

 

 

 

     
 

 

Item 2.02 Results of Operations and Financial Condition.

 

On June 7, 2018, Advaxis, Inc. (the “Company”) issued a press release announcing results of operations for the three months ended April 30, 2018 and providing a business update. The Company also hosted an investor conference call on June 7, 2018, during which the Company provided a business update and a brief overview of its financial results. A copy of such press release is being furnished as Exhibit 99.1 to this report.

 

Item 9.01. Financial Statements and Exhibits.

 

(d) Exhibits.

 

The following exhibit is furnished as part of this report:

 

Exhibit

Number

  Description
     
99.1   Press release issued by Advaxis, Inc. dated June 7, 2018.

 

     
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

ADVAXIS, INC.
   

 

(Registrant)
Date: June 7, 2018    
  By: /s/ Kenneth A. Berlin
   

Kenneth A. Berlin

   

President and Chief Executive Officer

 

     
 

 

1 Year Ayala Pharmaceuticals (QX) Chart

1 Year Ayala Pharmaceuticals (QX) Chart

1 Month Ayala Pharmaceuticals (QX) Chart

1 Month Ayala Pharmaceuticals (QX) Chart

Your Recent History

Delayed Upgrade Clock